Free Trial
NASDAQ:BRTX

Biorestorative Therapies Q4 2023 Earnings Report

Biorestorative Therapies logo
$1.53 +0.02 (+1.32%)
Closing price 03:56 PM Eastern
Extended Trading
$1.54 +0.00 (+0.33%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biorestorative Therapies EPS Results

Actual EPS
-$0.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biorestorative Therapies Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.03 million
Beat/Miss
Missed by -$10.00 thousand
YoY Revenue Growth
N/A

Biorestorative Therapies Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, April 1, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Biorestorative Therapies' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Biorestorative Therapies Earnings Headlines

Roth Capital Issues Positive Estimate for BRTX Earnings
Tax Drain Deadline: Protect Your Wealth Before September 15th
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
Earnings Outlook For BioRestorative Therapies
See More Biorestorative Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biorestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biorestorative Therapies and other key companies, straight to your email.

About Biorestorative Therapies

Biorestorative Therapies (NASDAQ:BRTX), a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

View Biorestorative Therapies Profile

More Earnings Resources from MarketBeat